Current CML therapy is based upon highly specific targeted drugs, tyrosine kinase inhibitors (TKI), specifically blocking p210 - imatinib and its analogues. This evidence concerns the gene EVPL and chronic myelogenous leukemia, BCR-ABL1 positive.